Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYP Profiling in Healthy Subjects and Liver Cirrhosis Patients
NCT05741385Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of caffeine, warfarin, omeprazole, metoprolol and midazolam (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration Time Curve of Caffeine, Omeprazole and Metoprolol in Plasma Over the Time Interval From 0 to 24 Hours, Area Under the Concentration Time Curve of Midazolam in Plasma Over the Time Interval From 0 to 24 Hours and 2 more. Started Oct 2023; status: completed.
02
Drugs
caffeinewarfarinomeprazolemetoprololmidazolam
Beyond the preview
Go deeper on NCT05741385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05741385.